Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...
2023
Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership
Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...
CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...
Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC
The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...
Baxter Appoints Wu Xin as China General Manager Amid Spin-Off of Kidney Care Business
Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu...
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report...
EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...
Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
Lepu ScienTech Reports 33% Revenue Growth in 2023 Interim Report
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd, (HKG: 2291) a China-based medical technology company, has...
Japan’s MHLW Approves Eisai and BioArctic’s Leqembi for Alzheimer’s Treatment
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted approval to Eisai...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that a Phase III trial for its...
AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China
AffaMed Therapeutics, a China-based biotech firm, has announced the receipt of its first clinical trial...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...
Shanghai Junshi’s Tuoyi Meets Primary Efficacy Endpoint in Phase III Melanoma Study
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
CDE Introduces New Guidelines for Generic Drug Quality and Efficacy Consistency Evaluation
The Center for Drug Evaluation (CDE) has released a new set of Guidelines for “the...
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...
Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...